Ayr Wellness (AYR-A) Q4 2024 earnings summary

Executive summary

• Leadership changes include elevation of George DeNardo to President, appointment of co-Chief Revenue Officers, and ongoing search for new CEO and CFO, with a focus on operational discipline and streamlining.

• The company is prioritizing sustainable growth and profitability within its existing footprint, emphasizing operational efficiency and cost discipline.

• Strategic focus is on core markets: Florida, Nevada, New Jersey, Pennsylvania, Ohio, and Massachusetts, with divestiture plans for non-core assets like Illinois.

• Strategic investments include a new indoor cultivation facility in Florida and expansion into Ohio and Virginia.

• Q4 and FY 2024 results reflect ongoing macroeconomic pressures and company-specific challenges impacting revenue and profitability.

Financial highlights

• Q4 2024 revenue was $114 million, down 0.7% year-over-year and 0.3% sequentially, in line with guidance; FY 2024 revenue flat at $463.6 million.

• Q4 2024 gross profit was $35.8 million, down 27% year-over-year and 17% from the prior quarter; FY 2024 gross profit was $176.7 million, down 12.7%.

• Q4 2024 adjusted EBITDA was $19.1 million (16.7% margin), down 35.9% year-over-year; FY 2024 adjusted EBITDA was $100 million (21.6% margin), down 12.3%.

• Q4 2024 loss from continuing operations was $133.9 million, including $116 million in non-cash impairment charges; FY 2024 net loss attributable to Ayr Wellness was $359.3 million.

• Q4 2024 operating loss was $133.9 million, including $94 million Florida goodwill impairment; FY 2024 operating loss $161 million.

Outlook and guidance

• Q1 2025 revenue expected to decline mid-single digits from Q4 2024, with a modest increase in adjusted EBITDA margin.

• FY 2025 capital expenditures projected at $10 million, down from $17.7 million in FY 2024; any Virginia investment incremental.

• Continued focus on positive cash flow from operations despite ongoing margin pressures.